Video

Dr David Blumenthal Weighs in on the Effect of King v. Burwell Decision

On March 4 the Supreme Court will hear arguments in the case of King v. Burwell, which determines the fate of subsidies in the 34 federally facilitated marketplaces, and David Blumenthal, MD, chief executive officer of The Commonwealth Fund, outlined the potentially catastrophic effects if the Court were to side with the plaintiffs.

On March 4 the Supreme Court will hear arguments in the case of King v. Burwell, which determines the fate of subsidies in the 34 federally facilitated marketplaces, and David Blumenthal, MD, president of The Commonwealth Fund, outlined the potentially catastrophic effects if the Court were to side with the plaintiffs.

A ruling that strikes down subsidies for individuals on the federal marketplace would not only affect those who were relying on the assistance for health insurance, he explained. Some providers, particularly safety net providers, would suffer financial losses that would make it difficult to treat all patients, not just those directly affected by the court ruling.

“We see lots of negative side effects and certainly are concerned that some of the very important gains that have been made under the Affordable Care Act—with respect to access to care, reduction of medical debt, reduction of financial barriers to care—that some of those very important gains would be lost,” Dr Blumenthal said.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Merrill H. Stewart, MD
Dr Carrie Kitko
Jeffrey Fitzgerald, JD
Dr Carrie Kitko
Merrill H. Stewart, MD
Nicolas Ferreyros, managing director, Community Oncology Alliance
Dr Ibrahim Aldoss
Jody Agena, PharmD, MBA, director of pharamcy operations, Virginia Cancer Specialists
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo